comparemela.com
  1. Home
  2. Live Updates
  3. Urothelial - Breaking News

Latest Breaking News On - Urothelial - Page 1 : comparemela.com

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement. | June 9, 2023

New jerseyUnited statesUrogen pharma ltdUrogen pharmaUrogen pharma ltd stock exchangePress releaseF urgn il0011407140

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the. | June 2, 2023

Urogen pharma ltdGoldman sachsUrogen pharmaChat dateAnnual global healthcare conferenceUrogen pharma ltd stock exchangePress releaseT urgn il0011407140

UroGen Pharma - New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO in the Treatment of UTUC of the Ureter and Renal Pelvis

PRINCTON - UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a. | May 1, 2023

United statesMark schoenbergJoseph jacobUrogen rtgelBladder cancer programAmerican urological association meetingUrogen pharma ltdExchange commissionGen pharmaFirst analysisUreteral tumorsMedical universityChief medical officerPrivate securities litigation reform actRisk factorsStates securities

First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation

New Retrospective Study Presented at AUA 2023 Reports Use of JELMYTO in Treating Patients with Upper Tract Urothelial Cancer After Complete Endoscopic Ablation . | May 1, 2023

United statesUrogen rtgelMark schoenbergUrogen pharmaUrogen pharma ltdExchange commissionNephrostomy administrationDrug administrationAmerican urological association meetingCenter evaluation of practice patternsMitomycin gelUpper tract urothelial carcinoma early experienceUpper tract urothelial cancerMulti center evaluationPractice patternsChief medical officer

New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis. | April 30, 2023

United statesJoseph jacobUrogen pharmaMark schoenbergUrogen pharma ltdAmerican urological association meetingBladder cancer programNephrostomy administrationDrug administrationFirst analysisUreteral tumorsUpstate medical universityChief medical officerUpper tract urothelial cancerPrescribing informationPatient information

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.